Alterity Therapeutics Limited (ATHE): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATHE Stock Price Chart Interactive Chart >
ATHE Price/Volume Stats
| Current price | $0.68 | 52-week high | $2.75 |
| Prev. close | $0.67 | 52-week low | $0.58 |
| Day low | $0.67 | Volume | 22,000 |
| Day high | $0.68 | Avg. volume | 1,469,901 |
| 50-day MA | $0.75 | Dividend yield | N/A |
| 200-day MA | $0.98 | Market Cap | 15.30M |
Alterity Therapeutics Limited (ATHE) Company Bio
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
Latest ATHE News From Around the Web
Below are the latest news stories about Alterity Therapeutics Ltd that investors may wish to consider to help them evaluate ATHE as an investment opportunity.
Alterity announces publication of animal study on lead assetAlterity Therapeutics (ATHE) has added ~10% in the pre-market after announcing that the Journal of Parkinson''s Disease published data from an animal study, which was designed to |
Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's DiseaseAlterity Therapeutics's (NASDAQ: ATHE) data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. The publication describes a study evaluating the efficacy of ATH434 in genetically altered mice that develop manifestations of MSA. The investigation demonstrated that ATH434 treatment reduced both the toxic oligomeric and aggregated forms of α–synuclein, a central nervous system protein essential for the normal function of nerve cells. At the same |
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's DiseaseAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. MSA is a devastating neurodegenerative disorder without approved therapy. |
Appendix 4C - Q2 FY22 Quarterly Cash Flow ReportAlterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2021 (Q2 FY22). |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's the final day of trading this week and we're starting it off with an overview of the biggest pre-market stock movers for Friday! |
ATHE Price Returns
| 1-mo | -5.56% |
| 3-mo | -16.85% |
| 6-mo | -33.33% |
| 1-year | -49.25% |
| 3-year | -48.97% |
| 5-year | -67.77% |
| YTD | -5.56% |
| 2021 | -46.27% |
| 2020 | 71.79% |
| 2019 | -39.06% |
| 2018 | -58.97% |
| 2017 | 91.41% |
Loading social stream, please wait...